Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Original Research
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 16,057 | Dovepress* | 11,987+ | 1,857 | 13,844 | |
| PubMed Central* | 4,070 | 1,038 | 5,108 | ||
| Totals | 16,057 | 2,895 | 18,952 | ||
| *Since 13 February 2017 | |||||
View citations on PubMed Central and Google Scholar